New hope for advanced cancer: VIB305 trial opens for patients out of options
NCT ID NCT07222969
First seen Oct 31, 2025 · Last updated May 04, 2026 · Updated 24 times
Summary
This study tests an experimental drug, VIB305, in people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. The trial has two parts: first, finding the safest dose, and then testing that dose in more patients to see if it shrinks tumors. About 146 adults will take part, and the goal is to understand safety and whether the drug can help control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
-
Sunshine Coast University Private Hospital
RECRUITINGSunshine Coast, Australia
Contact
Conditions
Explore the condition pages connected to this study.